Treating venous thromboembolism: enoxaparin.
This article reviews the developments that have occurred in the treatment of venous thromboembolism during the last decade, with emphasis on the establishment of low molecular weight heparin as a therapeutic agent of proven efficacy and examines the evidence that supports the movement from inpatient to outpatient hospital management of venous thromboembolism.
Perry
D J
DJ
Haemophilia Centre and Haemostasis Unit, Royal Free and University College Medical School, Royal Free Campus, London NW3 2PF.
D000553:Ambulatory Care; D000925:Anticoagulants / Q000627:therapeutic use*; D000075202:Contraindications; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D017984:Enoxaparin / Q000627:therapeutic use*; D006760:Hospitalization; D006801:Humans; D009765:Obesity / Q000150:complications; D017410:Practice Guidelines as Topic; D011655:Pulmonary Embolism / Q000188:drug therapy; D051437:Renal Insufficiency / Q000150:complications; D013923:Thromboembolism / Q000188:drug therapy*; D020246:Venous Thrombosis / Q000188:drug therapy*
D000925:Anticoagulants; D017984:Enoxaparin